Illumina Inc. ($ILMN) Stock Forecast: Up 5.2% Today

What is Illumina Inc.?

ILMN (Illumina Inc.) is a leading biotechnology company that focuses on genetic research tools and molecular diagnostics. The company is known for its innovative products in the field of genomics. Illumina stock (ILMN) experienced a strong bullish movement recently. Illumina made a $350 million acquisition deal with SomaLogic to enhance its multiomics strategy. The acquisition of SomaLogic is a significant step in Illumina's advanced biomarker push, with profitability expected by 2027.

Why is Illumina Inc. going up?

ILMN stock is up 5.2% on Jun 26, 2025 14:45

• The positive market sentiment surrounding Illumina's acquisition of SomaLogic likely contributed to the bullish movement in the company's stock.
• Investors' optimism about the potential synergies and growth opportunities from the SomaLogic deal is driving increased buying interest in Illumina.
• The market's response reflects confidence in Illumina's long-term strategy and its position to benefit from the rising demand for advanced biomarker technologies in the biotechnology sector.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina Stock May Benefit From New Agreement to Acquire SomaLogic

ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.

https://www.zacks.com/stock/news/2554296/illumina-stock-may-benefit-from-new-agreement-to-acquire-somalogic

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push - Illumina ( NASDAQ:ILMN ) , Standard BioTools ( NASDAQ:LAB )

Illumina to pay $350 million in cash and up to $75 million in milestones to acquire SomaLogic. Deal expected to close in H1 2026; profitability anticipated by 2027. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. On Monday, Illumina, Inc.

https://www.benzinga.com/m-a/25/06/46056588/somalogic-acquisition-worth-350-million-marks-next-step-in-illuminas-advanced-biomarker-push

FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?

FTRE vs. ILMN: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2520783/ftre-vs-ilmn-which-stock-should-value-investors-buy-now

Trending Today

Algorand ($ALGO) Crypto Forecast: Up 5.0% Today

Arbitrum ($ARB) Crypto Forecast: Down 9.6% Today

Bitcoin Cash ($BCH) Crypto Forecast: Up 5.0% Today

Sui ($SUI) Crypto Forecast: Down 5.1% Today

Ethena ($ENA) Crypto Forecast: Down 5.2% Today

Pepe ($PEPE) Crypto Forecast: Down 5.1% Today

Cardano ($ADA) Crypto Forecast: Up 5.2% Today

XRP ($XRP) Crypto Forecast: Up 6.2% Today

Apple Inc. ($AAPL) Stock Forecast: Up 2.3% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 6.7% Today

Illumina Inc. Price History

25.05.2025 - ILMN Stock was up 4.0%

• Today, Illumina experienced strong bullish movement following its acquisition of SomaLogic. This strategic move aims to enhance Illumina's biomarker capabilities and solidify its position in the healthcare sector.
• The acquisition is viewed favorably as it enriches Illumina's product portfolio and diversifies its revenue streams, sparking investor optimism and increasing stock interest.
• Comparative value analysis positions Illumina as a standout among its peers, underlining the market's acknowledgment of its growth potential and future profitability. This recognition further amplifies investor trust and propels the stock price upward.

05.02.2025 - ILMN Stock was up 5.3%

• Illumina stock experienced a strong bullish movement today.
• The stock might have surged due to the outperforming market performance over the past 20 years, with an average annual return of 17.25%.
• The drop in revenue from China and the ban on Illumina's gene sequencers might have initially caused a dip in the stock price, but investors seem to be focusing more on the long-term performance and growth potential of the company.
• Despite the short-term challenges, the positive long-term outlook and historical performance of Illumina could be driving the bullish movement in the stock today.

26.02.2025 - ILMN Stock was down 5.1%

• Today's decline in ILMN stock could be linked to:
• Completion of Illumina's AGD project sequenced 250,000 whole genomes, causing concerns about future growth and prompting investors to take profits.
• Ark Invest selling off Illumina shares, possibly leading other investors to follow suit after Cathie Wood's fund reduced its position in the company.
• Shifting market sentiment towards biotech stocks with investors redirecting investments to companies such as Iridium, Beam, and Pacific Biosciences, which were favored by Ark Invest over Illumina.

26.05.2025 - ILMN Stock was up 5.2%

• The positive market sentiment surrounding Illumina's acquisition of SomaLogic likely contributed to the bullish movement in the company's stock.
• Investors' optimism about the potential synergies and growth opportunities from the SomaLogic deal is driving increased buying interest in Illumina.
• The market's response reflects confidence in Illumina's long-term strategy and its position to benefit from the rising demand for advanced biomarker technologies in the biotechnology sector.

21.04.2025 - ILMN Stock was down 5.1%

• The bearish movement in ILMN stock today could be attributed to profit-taking by investors after a recent strong bullish run.
• Despite the positive news about the launch of the new DRAGEN v4.4 software, the market may have reacted negatively due to potential concerns about the actual impact on the company's financial performance.
• Significant increase in stake in Illumina by an influential investor might have initially boosted investor confidence, but the overall market sentiment may have been influenced by broader industry trends or macroeconomic factors impacting biotech stocks.
• It's possible that the market perceived ILMN's current valuation as stretched, leading to a correction despite the positive developments.

06.04.2025 - ILMN Stock was down 5.0%

• The bearish movement in ILMN today could be due to profit-taking by investors after a recent bullish run.
• Despite the positive expectations for earnings growth, market participants might have been disappointed by other underlying factors.
• It's possible that some investors were expecting even stronger performance, leading to a sell-off in the stock.
• Short-term market fluctuations can sometimes overshadow long-term growth prospects, causing abrupt price changes like the one observed today.

03.03.2025 - ILMN Stock was down 5.4%

• Keith Meister joining Illumina's board suggests the possibility of strategic shifts or growth endeavors within the company.
• Although Illumina has historically performed well, recent market reactions may reflect concerns or uncertainties related to the influence of the new board member on future decisions.
• Investors may be hesitant about potential alterations in Illumina's direction under Meister's guidance, prompting a short-term sell-off of the company's stock.

12.02.2025 - ILMN Stock was down 6.5%

• Plans to cut $100 million in costs by 2025 due to China trade restrictions impacting a significant portion of its sales have led to a lowered profit outlook. This news likely contributed to the bearish movement in the stock.
• The decision to lower its 2025 adjusted EPS guidance to $4.50, at the lower end of the range, reflects the challenges faced in the current trade environment.
• Despite some unusual bullish options activity noted by investors, the overall sentiment towards Illumina seems to have been overshadowed by the negative impact of the trade tensions and cost-cutting measures.

27.01.2025 - ILMN Stock was down 6.3%

• Despite Illumina's strong track record and partnerships within the biotech industry, its stock showed bearish trends in the market.
• The stock's decline could be attributed to various economic conditions or industry-specific updates affecting biotech stocks.
• Investors might be capitalizing on previous gains, causing a temporary decrease in the stock value.
• Monitoring Illumina's collaborations and technological progress will be crucial in predicting its future market performance.

22.03.2025 - ILMN Stock was up 5.1%

• Rep. Thomas Kean's recent notable acquisition of Illumina stock could be perceived as an endorsement of the company's future potential, which might positively impact investor confidence.
• The disclosure regarding insider purchasing actions likely influenced the upward momentum of Illumina's stock price today.
• Market participants could view this internal transaction as a favorable sign, potentially prompting heightened purchasing activity and contributing to the stock's upward trajectory.

09.04.2025 - ILMN Stock was down 5.0%

• Despite surpassing earnings and revenue estimates in Q1 of 2025, Illumina Inc. (ILMN) experienced a bearish movement.
• The market may have reacted negatively due to the year-over-year decrease in revenues, indicating potential concerns about future growth prospects.
• Investors might be cautious about the sustainability of Illumina's performance, leading to profit-taking and a downward pressure on the stock price.
• The slight misses in earnings and revenue estimates could have also contributed to the bearish sentiment, as investors may have been expecting even stronger results.

09.04.2025 - ILMN Stock was down 5.1%

• Despite surpassing Q1 earnings and revenue estimates, a downtrend was observed in the stock's movement.
• Potential high expectations from investors for even stronger results post-earnings might have triggered a sell-off.
• The market sentiment might have been influenced by general economic conditions or uncertainties about future growth prospects.
• Some investors may have opted for profit-taking, capitalizing on the recent upsurge in the stock.